产品
编 号：F271682
分子式：C22H21BrO3
分子量：413.3
分子式：C22H21BrO3
分子量：413.3
产品类型
规格
价格
是否有货
结构图
CAS No: 2123480-72-6
产品详情
生物活性：
UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme UbcH5c, with a Kd of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85. A promising lead compound for the development of new antirheumatoid arthritis (RA) agent.
体内研究：
UbcH5c-IN-1 (compound 6d) (5 and 20 mg/kg, p.o., daily, 10-20 days) treatment in Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model results in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.Animal Model:Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model.
Dosage:5 and 20 mg/kg
Administration:Oral administration daily between day 10-20 postimmunization.
Result:Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.
UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme UbcH5c, with a Kd of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85. A promising lead compound for the development of new antirheumatoid arthritis (RA) agent.
体内研究：
UbcH5c-IN-1 (compound 6d) (5 and 20 mg/kg, p.o., daily, 10-20 days) treatment in Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model results in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.Animal Model:Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model.
Dosage:5 and 20 mg/kg
Administration:Oral administration daily between day 10-20 postimmunization.
Result:Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备